Multicentre study to determine the Etest epidemiological cut-off values of antifungal drugs in Candida spp. and Aspergillus fumigatus species complex

• Published in: Clinical microbiology and infection Vol. 25; no. 12; pp. 1546 - 1552
• Main Authors: Salsé, M., Gangneux, J.-P., Cassaing, S., Delhaes, L., Fekkar, A., Dupont, D., Botterel, F., Costa, D., Bourgeois, N., Bouteille, B., Houzé, S., Dannaoui, E., Guegan, H., Charpentier, E., Persat, F., Favennec, L., Lachaud, L., Sasso, M.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.12.2019; Elsevier for the European Society of Clinical Microbiology and Infectious Diseases
• Subjects: Antifungal agents; Antifungal Agents - pharmacology; Aspergillus; Aspergillus fumigatus - drug effects; Aspergillus fumigatus - isolation & purification; Candida; Candida - drug effects; Candida - isolation & purification; Disk Diffusion Antimicrobial Tests; Drug Resistance, Fungal; Endpoint Determination; Epidemiological cut-off values; Etest; France - epidemiology; Humans; Life Sciences; Microbial Sensitivity Tests - standards; Microbial Sensitivity Tests - statistics & numerical data; Mycoses - epidemiology; Mycoses - microbiology; Retrospective Studies; France; Aspergillus; Epidemiological cut-off values; Etest; Candida; Antifungal agents
• ISSN: 1198-743X; 1469-0691
• DOI: 10.1016/j.cmi.2019.04.027

To determine the Etest-based epidemiological cut-off values (ECVs) for antifungal agents against the most frequent yeast and Aspergillus fumigatus species isolated in 12 French hospitals. For each antifungal agent, the Etest MICs in yeast and A. fumigatus isolates from 12 French laboratories were retrospectively collected from 2004 to 2018. The ECVs were then calculated using the iterative statistical method with a 97.5% cut-off. Forty-eight Etest ECVs were determined for amphotericin B, caspofungin, micafungin, anidulafungin, fluconazole, voriconazole, posaconazole and itraconazole, after pooling and analysing the MICs of 9654 Candida albicans, 2939 Candida glabrata SC, 1458 Candida parapsilosis SC, 1148 Candida tropicalis, 575 Candida krusei, 518 Candida kefyr, 241 Candida lusitaniae, 131 Candida guilliermondii and 1526 Aspergillus fumigatus species complex isolates. These ECVs were 100% concordant (identical or within one two-fold dilution) with the previously reported Etest-based ECVs (when available), and they were concordant in 76.1% of cases with the Clinical and Laboratory Standards Institute ECVs and in 81.6% of cases with the European Committee on Antimicrobial Susceptibility Testing ECVs. On the basis of these and other previous results, we recommend the determination of method-dependent ECVs. Etest ECVs should not be used instead of breakpoints, but may be useful to identify non-wild-type isolates with potential resistance to antifungal agents, and to indicate that an isolate may not respond as expected to the standard treatment.